Unleashing the Immune System: Blocking a Key Enzyme Could Make Immunotherapy Work for More Cancer Types
Certain cancers have proven resistant to immunotherapy, leaving many patients with fewer treatment options. A groundbreaking study from the University of Michigan Rogel Cancer Center could change that.
The research, published in Cancer Discovery, pinpoints a new target: the UBA1 enzyme. While known to contribute to tumor growth, UBA1’s role in suppressing the immune response was previously unknown.
Inhibiting UBA1, researchers discovered, significantly increases the activity of immune cells that attack tumors. This opens the door to a new treatment strategy: combining UBA1 inhibitors with existing immunotherapies, broadening the reach of these powerful cancer therapies.
“We’ve seen remarkable clinical successes with immunotherapies, especially with this checkpoint therapy,” said Arul M. Chinnaiyan, M.D., Ph.D., reminding us of the potent impact of NSD these treatments. However, it hasn’t been uniform success. Certain cancers, often labeled "cold" tumors due to their lack of immune cells, haven’t responded as well. "[Stubs] Chemo and radiation have limited this. For example, kidney cancers, some melanomas, and non-small cell lung cancers respond well to immune checkpoint blockade" which work
Intriguingly, the UBA1 enzyme isn’t just present in tumors:
certain cancer types, not everyone responds equally to these innovative treatments. "One of the biggest challenges has been how to expand this effectiveness to treat more
people," Chinnaiyan explained.
This study focused on prostate cancer, a prime example of a tumor often unresponsive to immunotherapy. Researchers Delving deeper, the team analyzed genetic data from 208 metastasized prostate tumors, uncovering the experience.
"We just don’t see as strong
Let’s look at the findings from this groundbreaking research. The researchers focused on.
The results suggested pre-existing T-
These UBA1, in context, after observing
Hesitation, or – cellular activity. Taking UBA1
Mice.
blockade therapies could help
with less. This news could be completely transformative for patients with these hard-to-treat cancers who have had limited options, and shed light on therapies for enhancing
research wasn’t just limited to theoretical analysis. They
of urological cancers, which include less UBA1. Just eighty-six percent Turning these preclinical findings into practical therapy, they treated a group
Survivors since.
Here’s how this exceptional work transformed into is pointing us in the right direction:
of
"We’ve laid
," Chinnaiyan shared, emphasizing both limitation of the study focus on tumor investigation
“We’re excited because found not UBA1
development of
molecule." However, Chinnaiyan cautioned that more research
The Future of Cancer Treatment
This groundbreaking research opens the door to new possibilities,
What are the potential treatment implications of inhibiting UBA1 in combination with existing immunotherapies?
## Unleashing the Immune System: Interview with Dr. Chinnaiyan on New Cancer Treatment
Welcome back to the show. Today, we’re discussing a groundbreaking new study from the University of Michigan Rogel Cancer Center that could revolutionize cancer treatment. Joining us is Dr. Arul M. Chinnaiyan, the lead researcher behind this exciting discovery. Dr. Chinnaiyan, thank you for being here.
**Dr. Chinnaiyan:** Thank you for having me.
**Host:** Let’s talk about this new discovery. Your team has identified a key enzyme, UBA1, that seems to play a critical role in hindering the effectiveness of immunotherapy. Can you explain what UBA1 is and how it works?
**Dr. Chinnaiyan:** Absolutely. UBA1 is an enzyme that’s been known to contribute to tumor growth. What we’ve recently discovered is that UBA1 also suppresses the immune response, essentially acting as a shield for cancer cells. This explains why certain cancers, often called “cold tumors” because of their low immune cell presence, haven’t responded well to immunotherapy.
**Host:** This is fascinating. So, by blocking UBA1, you’re essentially removing this shield and allowing the immune system to attack the cancer cells more effectively?
**Dr. Chinnaiyan:** Exactly! Inhibiting UBA1 significantly increases the activity of immune cells that target tumors. This opens up new avenues for treatment.
**Host:**
And what kind of treatments are we talking about?
**Dr. Chinnaiyan:** We envision combining UBA1 inhibitors with existing immunotherapies, like checkpoint blockade therapy. This could potentially make immunotherapy more effective for a wider range of cancers, including those that haven’t responded well in the past.
**Host:** This is incredibly promising news for cancer patients. Are there any UBA1 inhibitors currently available, or are they still in development?
**Dr. Chinnaiyan:** There are some UBA1 inhibitor drugs, like TAK-243, that have shown some success [[1](https://www.genengnews.com/topics/cancer/cancer-immunotherapy-could-turn-up-the-heat-on-cold-tumors-by-suppressing-uba1/) ]. We believe pairing them with existing immunotherapies could significantly enhance their effectiveness.
**Host:** Dr. Chinnaiyan, this research is groundbreaking. Thank you for sharing your insights with us today.
**Dr. Chinnaiyan:** My pleasure. We are incredibly excited about the potential of this discovery to help more cancer patients.
**Host:** We are, too. This is certainly a development we’ll be watching closely.
